Please select the option that best describes you:
Do you have any advice when utilizing palliative radiation therapy in patients currently being treated with a PARP inhibitor?
Can the drug continue during radiation therapy or should it be discontinued at a specified time prior to initiation of radiation?
Answer from: Radiation Oncologist at Academic Institution
This is an excellent question and certainly will become more of an issue with the recent FDA approval of olaparib for HR-defective (HRD) metastatic ovarian cancer. In addition, many other HRD metastatic cancers are being treated with this drug under compassionate use. Furthermore, the recent Ph...
Sign in or Register to read more